Business Model Breakdown
How Glaukos Corp Makes Money
GKOS
Market Cap
$7.9B
Annual Revenue
$151M
Profit Margin
-37.0%
The Short Version
Glaukos Corp develops and sells innovative medical devices and sustained drug delivery systems for treating chronic eye diseases, primarily glaucoma and corneal disorders. Its revenue comes from the sales of its proprietary products, such as the iStent for micro-invasive glaucoma surgery (MIGS) and iDose TR, which continuously delivers medication for months after a single implantation, directly to eye surgeons and clinics. The company aims to provide less invasive, more effective, and convenient solutions for patients, generating recurring sales through product adoption and utilization.
Where the Revenue Comes From
Glaucoma Devices & Sustained Drug Delivery (e.g., iStent, iDose TR) - approximately 85% of Q1 2026 net sales.
Corneal Health (e.g., Epioxa) - approximately 15% of Q1 2026 net sales.
Who buys: Ophthalmologists, eye surgeons, ambulatory surgical centers, and hospitals specializing in eye care.
Why It Works (Competitive Advantages)
- ✔Proprietary IP and first-mover advantage in Micro-Invasive Glaucoma Surgery (MIGS) with iStent.
- ✔Unique sustained drug delivery platform (iDose TR) creating a new market segment.
- ✔Established relationships and strong brand recognition among ophthalmologists.
Economic Moat: Narrow (Intangible Assets/IP (Extensive patent portfolio for iStent, iDose TR, Epioxa), Switching Costs (Surgeon training, familiarity, and clinical integration of devices), Efficient Scale (Specialized sales force and distribution network in ophthalmology))
What Our Analysis Says
DVR Score as of May 9, 2026
Glaukos continues to demonstrate strong execution, evidenced by a significant Q1 2026 revenue beat (+41% YoY) and an improving profitability trajectory (narrowing losses, expanding gross margins). The robust commercialization of iDose TR and a permanent J-code for Epioxa solidify its market leadership in the expanding MIGS and sustained drug delivery segments. The company boasts an excellent balance sheet with substantial cash and zero debt, providing a strong foundation for future growth. While insider selling by the CFO remains a minor concern, the overall financial performance and strategic positioning suggest a clearer path to profitability and substantial upside, mitigating previous concerns about execution challenges. The company's innovative IP and expanding TAM support a compelling 10x growth potential.